Industry News
Combining the old and new to kill cancer cells
3/26/2015
A team of Singapore based scientists have found that pairing a new approach with an old drug may be an effective approach to treat common cancers. In a landmark study, Professor David Virshup and Dr.
TSRI team discovers enzyme that keeps blood stem cells functional to prevent anemia
3/26/2015
Stem cells can generate any type of cell in the body, but they are inactive most of the time--and for good reason.
Ovarian cancer treatment set to improve following biomarker discovery
3/25/2015
The discovery of a biomarker that predicts the response to chemotherapy in patients with the most malignant form of ovarian cancer will help lead to better treatment options.
Favorable 15-year survival outcomes for older prostate cancer patients with low-risk disease
3/25/2015
Results from a population-based study from investigators at Rutgers Cancer Institute of New Jersey show favorable survival outcomes among patients with low-risk prostate cancer treated with...
Astellas Pharma Europe Ltd., in partnership with the Every Moment Matters Steering Committee, today announce results from a new survey of men living with prostate cancer across Europe.
Initial results from the Göteborg randomised screening trial indicates that using MRI (Magnetic Resonance Imaging) alongside conventional prostate cancer screening seems to offer improved cancer...
Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment, has announced study results demonstrating that its DecisionDx-Melanoma™ gene expression profile...
Anti-diabetic drug metformin and vitamin D3 show impressive promise in preventing colorectal cancer
3/25/2015
The concept was simple: If two compounds each individually show promise in preventing colon cancer, surely it's worth trying the two together to see if even greater impact is possible.
New treatment for mantle cell lymphoma (MCL) now available for patients in the UK
3/25/2015
VELCADE® (bortezomib) has been approved today in the UK for the first-line treatment of Mantle Cell Lymphoma (MCL), an aggressive subtype of blood cancers, collectively known as Non-Hodgkin...
Metabolic compensation underlies drug resistance in glioblastoma
3/25/2015
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM.